Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Banyu Terminates Copromotion of Singulair with Meiji Seika
August 2, 2010
- Pfizer: Torisel for RCC
August 2, 2010
- Shionogi to Create GDO to Accelerate Global Development
August 2, 2010
- Eli Lilly's Sales in Japan Up 36% in 1st Half of 2010
August 2, 2010
- NEW PRODUCTS
July 26, 2010
- Lorcaserin Induces Significant Weight Loss in PIII: Eisai
July 26, 2010
- Pariet to See Generics from 23 Companies in Nov.
July 26, 2010
- JELIS Trial Sub-Analysis Shows Significant Reduction in CAD by Epadel
July 26, 2010
- Foreign-Affiliated Research-Driven Companies Point out Need for Cautious Approach to Generics Business
July 26, 2010
- Dapagliflozin + Insulin Improve Glycemic Control in PIII: BMS, AZ
July 26, 2010
- Celgene's 2 Drugs for Multiple Myeloma Recommended for Approval
July 26, 2010
- Everolimus More Than Doubles PFS in pNET Patients
July 26, 2010
- All Candidates from Nichiiren Fail to Obtain Seat in Upper House
July 26, 2010
- Iressa Doubles PFS in Japanese NSCLC Patients with Mutated EGFR
July 26, 2010
- Parliamentary Secretary for Health Shinya Adachi Reelected
July 26, 2010
- Kobayashi to Develop More Class 1 OTC Drugs
July 26, 2010
- Dr Fujii Regains Seat in Upper House
July 26, 2010
- JPA to Renew Its Efforts to Increase Members' Awareness of New OTC Drug Sales System
July 26, 2010
- Standardize Interpretation of 1980 Notification: Chuikyo
July 26, 2010
- Erbitux Associated with Fewer Severe Infusion Reactions in Japan
July 26, 2010
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…